iScience (Oct 2023)

A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling

  • Jason A. Hackney,
  • Haridha Shivram,
  • Jason Vander Heiden,
  • Chris Overall,
  • Luz Orozco,
  • Xia Gao,
  • Eugene Kim,
  • Nathan West,
  • Aditi Qamra,
  • Diana Chang,
  • Arindam Chakrabarti,
  • David F. Choy,
  • Alexis J. Combes,
  • Tristan Courau,
  • Gabriela K. Fragiadakis,
  • Arjun Arkal Rao,
  • Arja Ray,
  • Jessica Tsui,
  • Kenneth Hu,
  • Nicholas F. Kuhn,
  • Matthew F. Krummel,
  • David J. Erle,
  • Kirsten Kangelaris,
  • Aartik Sarma,
  • Zoe Lyon,
  • Carolyn S. Calfee,
  • Prescott G. Woodruff,
  • Rajani Ghale,
  • Eran Mick,
  • Ashley Byrne,
  • Beth Shoshana Zha,
  • Charles Langelier,
  • Carolyn M. Hendrickson,
  • Monique G.P. van der Wijst,
  • George C. Hartoularos,
  • Tianna Grant,
  • Raymund Bueno,
  • David S. Lee,
  • John R. Greenland,
  • Yang Sun,
  • Richard Perez,
  • Anton Ogorodnikov,
  • Alyssa Ward,
  • Chun Jimmie Ye,
  • Thiru Ramalingam,
  • Jacqueline M. McBride,
  • Fang Cai,
  • Anastasia Teterina,
  • Min Bao,
  • Larry Tsai,
  • Ivan O. Rosas,
  • Aviv Regev,
  • Sharookh B. Kapadia,
  • Rebecca N. Bauer,
  • Carrie M. Rosenberger,
  • Yumiko Abe-Jones,
  • Michael Adkisson,
  • K. Mark Ansel,
  • Saurabh Asthana,
  • Alexander Beagle,
  • Sharvari Bhide,
  • Cathy Cai,
  • Saharai Caldera,
  • Maria Calvo,
  • Sidney A. Carrillo,
  • Suzanna Chak,
  • Stephanie Christenson,
  • Zachary Collins,
  • Spyros Darmanis,
  • Angela Detweiler,
  • Catherine DeVoe,
  • Walter Eckalbar,
  • Jeremy Giberson,
  • Ana Gonzalez,
  • Gracie Gordon,
  • Paula Hayakawa Serpa,
  • Alejandra Jauregui,
  • Chayse Jones,
  • Serena Ke,
  • Divya Kushnoor,
  • Tasha Lea,
  • Deanna Lee,
  • Aleksandra Leligdowicz,
  • Yale Liu,
  • Salman Mahboob,
  • Lenka Maliskova,
  • Michael Matthay,
  • Elizabeth McCarthy,
  • Priscila Muñoz-Sandoval,
  • Norma Neff,
  • Viet Nguyen,
  • Nishita Nigam,
  • Randy Parada,
  • Maira Phelps,
  • Logan Pierce,
  • Priya Prasad,
  • Sadeed Rashid,
  • Gabriella Reeder,
  • Nicklaus Rodriguez,
  • Bushra Samad,
  • Andrew Schroeder,
  • Cole Shaw,
  • Alan Shen,
  • Austin Sigman,
  • Pratik Sinha,
  • Matthew Spitzer,
  • Sara Sunshine,
  • Kevin Tang,
  • Luz Torres Altamirano,
  • Alexandra Tsitsiklis,
  • Erden Tumurbaatar,
  • Vaibhav Upadhyay,
  • Alexander Whatley,
  • Andrew Willmore,
  • Michael Wilson,
  • Juliane Winkler,
  • Kristine Wong,
  • Kimberly Yee,
  • Michelle Yu,
  • Mingyue Zhou,
  • Wandi S. Zhu

Journal volume & issue
Vol. 26, no. 10
p. 107813

Abstract

Read online

Summary: Altered myeloid inflammation and lymphopenia are hallmarks of severe infections. We identified the upregulated EN-RAGE gene program in airway and blood myeloid cells from patients with acute lung injury from SARS-CoV-2 or other causes across 7 cohorts. This program was associated with greater clinical severity and predicted future mechanical ventilation and death. EN-RAGEhi myeloid cells express features consistent with suppressor cell functionality, including low HLA-DR and high PD-L1. Sustained EN-RAGE program expression in airway and blood myeloid cells correlated with clinical severity and increasing expression of T cell dysfunction markers. IL-6 upregulated many EN-RAGE program genes in monocytes in vitro. IL-6 signaling blockade by tocilizumab in a placebo-controlled clinical trial led to rapid normalization of EN-RAGE and T cell gene expression. This identifies IL-6 as a key driver of myeloid dysregulation associated with worse clinical outcomes in COVID-19 patients and provides insights into shared pathophysiological mechanisms in non-COVID-19 ARDS.

Keywords